Trial Profile
An Open-label, Randomized, Parallel Design Trial to Compare the Efficacy of a Sitagliptin-based Metabolic Intervention Versus Standard Diabetes Therapy in Inducing Remission of Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Insulin glargine; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms REMIT-Sita
- 02 Nov 2021 Results published in the Diabetes Care
- 10 Dec 2019 Status changed from active, no longer recruiting to completed.
- 17 Jan 2019 Planned End Date changed from 1 Dec 2018 to 15 Sep 2019.